GliaSite® radiation therapy system: Radiation safety and dosimetric considerations

E. Capra, A. Drigo, C. Gobitti, E. Borsatti, F. Tuniz, B. Zanotti, M. Skrap, M. G. Trovò, M. Cimitan, M. Arcicasa, M. Roncadin, M. Burello, C. Cappelletto

Research output: Contribution to journalArticlepeer-review


Treatment of cerebral gliomas with the GliaSite® Radiation Therapy System has been performed in the United States since 2001. The procedure assumes the use of a spherical unsealed source containing 125I in liquid form. The amount of the activities utilized (GBq) is such that enacting appropriate radiation safety measures for the patient and personnel as prescribed by law and standards of good practice is a necessity. Dosimetry also requires special attention given the low energy of the radioisotope employed in therapy. In this study, the operative methods and results of radiation protection and dosimetric measurements performed on 10 patients in treatment with this system within our Institute between 2006 and 2007 are described.

Original languageEnglish
Pages (from-to)145-153
Number of pages9
JournalRivista Medica
Issue number4
Publication statusPublished - Dec 2007


  • Dosimetry
  • GliaSite®
  • Iodine 125
  • Radiation safety

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'GliaSite® radiation therapy system: Radiation safety and dosimetric considerations'. Together they form a unique fingerprint.

Cite this